Viatris Inc. is a global healthcare company that produces and markets a wide range of pharmaceutical products. Emerging from the merger between Mylan and Upjohn, a division of Pfizer, Viatris strives ... Viatris Inc. is a global healthcare company that produces and markets a wide range of pharmaceutical products. Emerging from the merger between Mylan and Upjohn, a division of Pfizer, Viatris strives to provide access to medications and healthcare solutions worldwide. The company's portfolio includes brands, general medicines, complex generics, and biosimilars, catering to a broad spectrum of therapeutic areas. Viatris operates across various sectors such as cardiovascular, oncology, dermatology, and infectious diseases, significantly impacting the health industry by striving to achieve sustainable access to medicines for patients.
Viatris is committed to leveraging scientific knowledge, regulatory expertise, and manufacturing capabilities to address global health challenges efficiently. By focusing on improving access and sustainability, Viatris plays a crucial role in advancing healthcare across diverse markets, particularly in delivering affordable medicinal solutions to underserved populations. With a robust supply chain and significant presence in numerous countries, Viatris exemplifies the integration of resources to support patient needs on a global scale, upholding its mission to empower people worldwide to live healthier at every stage of life.
Pending data availability
EU Taxonomy Data missing for Viatris
We haven’t collected EU Taxonomy data for Viatris yet, or the company
hasn’t made it publicly available.